- $329 million in third quarter global net product sales
- On track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023
- Results from the ADVANCE-IV study published in The Lancet
- Management to host conference call today at 1:30 pm CET (8:30 am ET)
The third quarter 2023 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website.
Dial-in numbers:
Please dial in 15 minutes prior to the live call.
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.